This discrepancy with previous results might be because different treatment methods for different stages of patients cause different immune responses in the body or because other factors affect TCR diversity, such as the tumor microenvironment, PD-1/PD-L1 signaling pathway, and T-cell memory subtypes. This evidence concerns the gene CD274 and neoplasm.